Polypeptide Composition Targeting Beta-Amyloid Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic methods for Alzheimer's dementia primarily alleviate symptoms rather than addressing the underlying causes, and there is a lack of effective food or drug materials for preventing or treating the disease, which is becoming increasingly prevalent due to the aging population.
Innovation Solution
A pharmaceutical and food composition containing a specific polypeptide sequence, such as Ln-X1-L-X2-V-X3-X4-X5-R-X6-L-X7, which suppresses lipopolysaccharide-mediated cytokine production, neuroinflammation, cognitive impairment, beta-amyloid and tau protein aggregation, and neuronal loss, and can pass through the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current therapeutic methods are used, then symptoms can be alleviated, but the fundamental cause of Alzheimer's disease cannot be solved
Solution Approach 1:
The patent identifies beta-amyloid as a harmful neurotoxic protein and uses it as a target for therapeutic intervention. By developing a peptide composition that specifically binds to and removes beta-amyloid from the brain, the invention converts the harmful presence of this protein into a treatable condition, addressing the fundamental cause rather than merely alleviating symptoms.
Solution Approach 2:
The patent introduces a peptide composition as an intermediary substance that mediates between the harmful beta-amyloid proteins and the brain tissue. This peptide acts as a therapeutic agent that selectively interacts with beta-amyloid to remove it from the brain, thereby treating the fundamental cause of Alzheimer's disease while maintaining safety.
2Quantity of substance
If there are no effective food raw materials or drugs, then the disease remains untreated, but the aging population increases the number of patients
Solution Approach 1:
The patent changes the chemical parameters of the treatment by synthesizing a specific peptide composition with a defined amino acid sequence (Ln-X1-L-X2-V-X3-X4-X5-R-X6-L-X7). This engineered peptide has specific binding properties for beta-amyloid that natural food materials do not possess, creating an effective treatment that can be manufactured through controlled chemical synthesis.
Solution Approach 2:
The patent creates a composite therapeutic approach by combining the synthesized peptide with appropriate pharmaceutical carriers and formulation excipients. This composite material formulation enables the peptide to be delivered effectively to the brain while maintaining stability and bioavailability, thus making the treatment manufacturable and administrable.
3Reliability
If a peptide composition is developed to target beta-amyloid, then the fundamental cause can be addressed, but the complexity of peptide synthesis and formulation increases
Solution Approach 1:
The patent segments the complex task of Alzheimer's treatment into a specific molecular target (beta-amyloid) and a corresponding specific therapeutic agent (the peptide composition). By focusing on this single target and designing a peptide that specifically addresses it, the invention simplifies the overall treatment approach compared to attempting to address multiple disease mechanisms simultaneously.
Solution Approach 2:
The patent uses a synthesized peptide that mimics or interacts with the beta-amyloid structure in a controlled manner. The peptide composition is designed to copy or bind to the harmful protein's structure, allowing the therapeutic agent to recognize and remove beta-amyloid specifically, thereby simplifying the treatment mechanism while maintaining effectiveness.
Data Source
AI summary
Provided is a peptide composition for preventing or treating Alzheimer's dementia. A peptide or a salt substituent thereof according to the presently claimed subject matter exhibits effects such as suppression of LPS-mediated cytokine production, suppression of LPS-induced neuroinflammation, amelioration of cognitive impairment, suppression of beta amyloid or tau protein aggregation, and suppression of neuronal loss. The polypeptide or the salt substituent thereof can permeate the blood-brain barrier, and thus, is expected to be usefully used for preventing or treating Alzheimer's dementia.